Vaccines against nicotine

Human Vaccines

Volumn 5, Issue 4, 2009, Pages 200-205

  Cerny, Erich H ^a   Cerny, Thomas ^b  

^a Chilka Ltd   (Switzerland)

^b Kantonsspital ^*  (Switzerland)

Author keywords

Bupropion; Celtic Pharma; Clinical trial; Commercialization; Cytos AG; Nabi Inc.; Nicotine vaccine; Pipeline; Varenicline

Indexed keywords

AMFEBUTAMONE; IMMUNOLOGICAL ADJUVANT; MONOAMINE OXIDASE INHIBITOR; NIB 002; NICOTINE; NICOTINE GUM; NICOTINE PATCH; NICOTINE VACCINE; NOSE SPRAY; PLACEBO; RIMONABANT; UNCLASSIFIED DRUG; VARENICLINE;

ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; BODY TEMPERATURE; CLINICAL TRIAL; COLD SENSATION; DOPAMINE BLOOD LEVEL; DOSAGE SCHEDULE COMPARISON; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; HUMAN; IMMUNOGENICITY; INHALER; LOADING DRUG DOSE; LOZENGE; MYALGIA; NICOTINE REPLACEMENT THERAPY; NONHUMAN; OSMOTIC PUMP; PATHOPHYSIOLOGY; PATIENT COUNSELING; PREVALENCE; REVIEW; SIDE EFFECT; SMOKING CESSATION; TOBACCO DEPENDENCE; TRANSDERMAL PATCH; TREATMENT DURATION; TREATMENT RESPONSE; VACCINE PRODUCTION; WITHDRAWAL SYNDROME;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES; CLINICAL TRIALS AS TOPIC; HUMANS; NICOTINE; SMOKING; VACCINES, CONJUGATE;

EID: 70349507294     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.5.4.7310     Document Type: Review

References (38)

1. Benowitz NL. Clinical pharmacology of nicotine: implications for understanding, preventing and treating tobacco addiction. Clin Pharmacol Ther 2008; 83:531-41.
2. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006; 3:442.
3. Fowler JS, Logan J, Wang GJ, Volkow ND. Monoamine oxidase and cigarette smoking. Neurotoxicol 2003; 24:75-82.
4. Swan GE, Benowitz NL, Lessov CN, Jacob P 3rd, Tyndale RF, Wilhelmsen K. Nicotine metabolism: the impact of CYP2A6 on estimates of additive genetic influence. Pharmacogenet Genomics 2005; 15:115-25.
5. Lessov-Schlaggar CN, Pergadia ML, Khroyan TV, Swan GE. Genetics of nicotine dependence and pharmacotherapy. Biochem Pharmacol 2008; 75:178-95.
6. Stead LF, Perera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev (Online) 2008; CD000146.
7. Le Foll B, George TP. Treatment of tobacco dependence: integrating recent progress into practice. CMAJ 2007; 177:1373-80.
8. Tonstad S, Tonnesen P, Hajek P, Williams KE, Billing CB, Reeves KR. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006; 296:64-71.
9. Fava M, Rush AJ, Thase ME, Clayton A, Stahl SM, Pradko JF, et al. 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. Prim Care Companion J Clin Psychiatry 2005; 7:106-13.
10. Wu P, Wilson K, Dimoulas P, Mills EJ. Effectiveness of smoking cessation therapies: a systematic review and meta-analysis. BMC Public Health 2006; 6:300.
11. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs. placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006; 296:56-63.
12. Schnoll RA, Patterson F, Lerman C. Treating tobacco dependence in women. J Womens Health (2002) 2007; 16:1211-8.
13. Siu EC, Tyndale RF. Non-nicotinic therapies for smoking cessation. Annu Rev Pharmacol Toxicol 2007; 47:541-64.
14. Hieda Y, Keyler DE, Ennifar S, Fattom A, Pentel PR. Vaccination against nicotine during continued nicotine administration in rats: immunogenicity of the vaccine and effects on nicotine distribution to brain. Int J Immunopharmacol 2000; 22:809-19.
15. Sanderson SD, Cheruku SR, Padmanilayam MP, Vennerstrom JL, Thiele GM, Palmatier MI, et al. Immunization to nicotine with a peptide-based vaccine composed of a conformationally biased agonist of C5a as a molecular adjuvant. Int Immunopharmacol 2003; 3:137-46.
16. Maurer P, Bachmann MF. Vaccination against nicotine: an emerging therapy for tobacco dependence. Expert Opinion Investig Drugs 2007; 16:1775-83.
17. Heading CE. Drug evaluation: CYT-002-NicQb, a therapeutic vaccine for the treatment of nicotine addiction. Curr Opin Investig Drugs 2007; 8:71-7.
18. Dyer MR, Renner WA, Bachmann MF. A second vaccine revolution for the new epidemics of the 21st century. Drug Discov Today 2006; 11:1028-33.
19. Maurer P, Bachmann MF. Therapeutic vaccines for nicotine dependence. Curr Opin Mol Ther 2006; 8:11-6.
20. Maurer P, Jennings GT, Willers J, Rohner F, Lindman Y, Roubicek K, et al. A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur J Immunol 2005; 35:2031-40.
21. Cerny T. Anti-nicotine vaccination: where are we? Recent Results Cancer Res 2005; 166:167-75.
22. Cornuz J, Zwahlen S, Jungi WF, Osterwalder J, Klingler K, van Melle G, et al. A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS ONE 2008; 3:2547.
23. Trial watch: Xenova's TA-NIC vaccine shows promise. Expert Rev Vaccines 2004; 3:386.
24. Goniewicz ML, Koszowski B, Czogala J, Zymelka A. [New prospects of nicotine dependence treatment - vaccines]. Przeg Lek 2006; 63:1114-8.
25. Heading CE. TA-CD. Xenova. IDrugs 2002; 5:1070-4.
26. Kosten TR, Rosen M, Bond J, Settles M, Roberts JS, Shields J, et al. Human therapeutic cocaine vaccine: safety and immunogenicity. Vaccine 2002; 20:1196-204.
27. Martell BA, Mitchell E, Poling J, Gonsai K, Kosten TR. Vaccine pharmacotherapy for the treatment of cocaine dependence. Biol Psychiatry 2005; 58:158-64.
28. Heading CE. NicVAX (Nabi Biopharmaceuticals). IDrugs 2003; 6:1178-81.
29. Hatsukami DK, Rennard S, Jorenby D, Fiore M, Koopmeiners J, de Vos A, et al. Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin Pharmacol Ther 2005; 78:456-67.
30. Keyler DE, Roiko SA, Earley CA, Murtaugh MP, Pentel PR. Enhanced immunogenicity of a bivalent nicotine vaccine. Int Immunopharmacol 2008; 8:1589-94.
31. Carrera MR, Ashley JA, Hoffman TZ, Isomura S, Wirsching P, Koob GF, et al. Investigations using immunization to attenuate the psychoactive effects of nicotine. Bioorg Med Chem 2004; 12:563-70.
32. Meijler MM, Matsushita M, Altobell LJ, 3rd, Wirsching P, Janda KD. A new strategy for improved nicotine vaccines using conformationally constrained haptens. J Am Chem Soc 2003; 125:7164-5.
33. Dickerson TJ, Yamamoto N, Janda KD. Antibody-catalyzed oxidative degradation of nicotine using riboflavin. Bioorg Med Chem 2004; 12:4981-7.
34. de Villiers SH, Lindblom N, Kalayanov G, Gordon S, Malmerfelt A, Johansson AM, et al. Active immunization against nicotine suppresses nicotine-induced dopamine release in the rat nucleus accumbens shell. Respiration 2002; 69:247-53.
35. Lindblom N, de Villiers SH, Kalayanov G, Gordon S, Johansson AM, Svensson TH. Active immunization against nicotine prevents reinstatement of nicotine-seeking behavior in rats. Respiration 2002; 69:254-60.
36. Cerny EH, Levy R, Mauel J, Mpandi M, Mutter M, Henzelin-Nkubana C, et al. Preclinical development of a vaccine 'against smoking'. Onkologie 2002; 25:406-11.
37. Hasman A, Holm S. Nicotine conjugate vaccine: is there a right to a smoking future? J Med Ethics 2004; 30:344-5.
38. Cerny T, Cerny EH. Reply to: Hasman A and Holm S. Nicotine conjugate vaccine: is there a right to a smoking future? J Med Ethics 2005; 31:558.